Discounted Cash Flow (DCF) Analysis Unlevered
Unity Biotechnology, Inc. (UBX)
$0.6099
-0.00 (-0.03%)
All numbers are in Millions, Currency in USD
Operating Data
Year A/P | 2017 Actual | 2018 Projected | 2019 Projected | 2020 Projected | 2021 Projected | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected |
| Revenue | 1.38 | - | - | - | - | - | - | - | - | - |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (%) | ||||||||||
| EBITDA | -43.35 | - | - | - | - | - | - | - | - | - |
| EBITDA (%) | ||||||||||
| EBIT | -44.66 | - | - | - | - | - | - | - | - | - |
| EBIT (%) | ||||||||||
| Depreciation | 1.30 | - | - | - | - | - | - | - | - | - |
| Depreciation (%) |
Balance Sheet Data
Year A/P | 2017 Actual | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected |
| Total Cash | 86.51 | - | - | - | - | - | - | - | - | - |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Cash (%) | ||||||||||
| Account Receivables | 1.38 | - | - | - | - | - | - | - | - | - |
| Account Receivables (%) | ||||||||||
| Inventories | - | - | - | - | - | - | - | - | - | - |
| Inventories (%) | ||||||||||
| Accounts Payable | 2.38 | - | - | - | - | - | - | - | - | - |
| Accounts Payable (%) | ||||||||||
| Capital Expenditure | -1.69 | - | - | - | - | - | - | - | - | - |
| Capital Expenditure (%) |
Weighted Average Cost Of Capital
| Share price | $ 0.6,099 |
|---|---|
| Beta | 0.638 |
| Diluted Shares Outstanding | 55.82 |
| Cost of Debt | |
| Tax Rate | 0.00 |
| After-tax Cost of Debt | -0.01% |
| Risk-Free Rate | |
| Market Risk Premium | |
| Cost of Equity | 6.004 |
| Total Debt | 51.56 |
| Total Equity | 34.04 |
| Total Capital | 85.60 |
| Debt Weighting | 60.23 |
| Equity Weighting | 39.77 |
| Wacc |
Build Up Free Cash
Year A/P | 2017 Actual | 2018 Projected | 2019 Projected | 2020 Projected | 2021 Projected | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected |
| Revenue | 1.38 | - | - | - | - | - | - | - | - | - |
|---|---|---|---|---|---|---|---|---|---|---|
| EBITDA | -43.35 | - | - | - | - | - | - | - | - | - |
| EBIT | -44.66 | - | - | - | - | - | - | - | - | - |
| Tax Rate | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIAT | -44.66 | - | - | - | - | - | - | - | - | - |
| Depreciation | 1.30 | - | - | - | - | - | - | - | - | - |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventories | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | - | - | - | - | - | - | - | - | - | - |
| Capital Expenditure | -1.69 | -1.26 | -1.59 | -0.65 | - | - | - | - | - | - |
| UFCF | -45.04 | - | - | - | - | - | - | - | - | - |
| WACC | ||||||||||
| PV UFCF | - | - | - | - | - | - | - | - | - | |
| SUM PV UFCF | - |
Terminal Value
| Growth in perpetuity method: | |
|---|---|
| Long-term growth rate | |
| WACC (%) | 2.38 |
| Free cash flow (t + 1) | - |
| Terminal Value | - |
| Present Value of Terminal Value | - |
Intrinsic Value
| Enterprise Value | - |
|---|---|
| Net Debt | 18.65 |
| Equity Value | - |
| Shares Outstanding | 55.82 |
| Equity Value Per Share | - |